Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Nexstim Oyj is a medical technology company specializing in the development of non-invasive brain stimulation systems. Primarily, Nexstim focuses on enhancing treatments for neurological and psychiatric disorders through innovative medical devices. Its flagship product, the Navigated Brain Stimulation (NBS) system, offers precision targeting for Transcranial Magnetic Stimulation (TMS), used extensively in neurosurgical planning and rehabilitation. The company's technology is pivotal in the diagnostics and treatment of conditions such as major depressive disorder, treatment-resistant depression, and brain tumors. Operating within the healthcare industry, Nexstim's contributions are notable for improving patient outcomes by enabling more accurate mapping of brain functions. Headquartered in Finland, Nexstim plays a crucial role in advancing medical standards, fostering the integration of advanced technology in routine clinical practices, and expanding its impact across Europe and North America. As a publicly traded entity, Nexstim Oyj represents a significant player in the intersection of healthcare and technology, illustrating the evolving landscape of medical treatment modalities.
€9.46
+€0.07 (+0.75%)
EOD Jul 2, 2026
Operating margin is thin at 5.80%. Limited cushion if revenue slows or costs rise, not the profile of a wide-moat business.
Revenue up 25.6% YoY with margins expanding 11.9pp. However, free cash flow softened 121%, worth monitoring whether this is timing or structural.
At 118x earnings, the current multiple leaves limited room for execution misses or growth deceleration. Free cash flow declined 121% versus the prior year, cash generation momentum has weakened.
118.3x earnings. The market is pricing in years of above-average growth. If that thesis breaks, downside from multiple compression alone could be 30%+. This is a stock where you're paying for the future, not the present.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
€11M
▲ +25.6% YoY
Net Income (TTM)
€573K
▲ +164.2% YoY
Op. Margin
5.80%
▲ +11.9pp YoY
ROIC
7.27%
▲ +12.4pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-€37K
▼ -121.3% YoY
Op. Cash Flow (TTM)
€1M
▲ +699.2% YoY
Net Debt
€1M
Cash & Equiv.
€3M
3Y CAGR: +4.8%
Continue Research
At a P/E of 118.3, Nexstim Oyj (NXTMH.XHEL)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Nexstim Oyj scores 12/100 on Intrinsiqq's quality scorecard, weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Nexstim Oyj scores 12 out of 100 on Intrinsiqq's quality score, a weighted blend of 7 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a 5.8% operating margin and a 7.3% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh NXTMH.XHEL's valuation and scores 12/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.